Abstract 264P
Background
Entrectinib is a CNS-active tyrosine kinase inhibitor that showed efficacy in pts with NTRK-fp solid tumours and ROS1-fp NSCLC from three phase 1/2 clinical trials (ALKA-372-001, EudraCT 2012-000148-88; STARTRK-1, NCT02097810; STARTRK-2, NCT02568267), including in a subset of Chinese (mainland China, Hong Kong, Taiwan) pts from STARTRK-2 (objective response rate [ORR]: 81% [NTRK-fp] and 63% [ROS1-fp]; data cutoff: 17 June 2021). We report updated data for this subset of patients, with a longer follow-up (enrolment/data cutoff: 17 Dec 2020/17 Dec 2021).
Methods
Chinese pts aged ≥18 years with locally advanced/metastatic NTRK-fp solid tumours or ROS1-fp NSCLC were enrolled. Tumour responses were assessed by blinded independent central review (BICR) per RECIST v1.1 at the end of Week 4 and every 8 weeks thereafter. Primary endpoints: ORR and duration of response (DoR). Key secondary endpoints: intracranial (IC) efficacy, time-to-event outcomes, and safety.
Results
The efficacy-evaluable population included 21 pts with NTRK-fp tumours (NSCLC n=11; sarcoma n=5; colon n=2; breast n=1; salivary n=1; thyroid n=1) and 38 pts with ROS1-fp NSCLC. Median survival follow-up was 16.7 mos (NTRK-fp tumours) and 36.6 mos (ROS1-fp NSCLC). In patients with NTRK-fp tumours, ORR was 81%. ORR in pts with ROS1-fp NSCLC was 66% (Table). The overall and IC results were in line with those reported in the overall study population. In the safety-evaluable NTRK-fp (n=32) and ROS1-fp (n=54) populations, 97% and 96% of pts reported treatment-related adverse events (TRAEs), respectively. Most were grade 1–2 and non-serious. TRAE-related discontinuation rates were 0% (NTRK-fp tumours) and 6% (ROS1-fp NSCLC).
Conclusions
This updated analysis with longer follow-up provides further evidence that entrectinib is associated with deep and durable responses in Chinese pts with NTRK-fp solid tumours or ROS1-fp NSCLC. Table: 264P
NTRK-fp tumours | ROS1-fp NSCLC | |||
Overall N=21 | Intracranial† n=5 | Overall N=38 | Intracranial† n=8 | |
ORR*, n (%) 95% CI | 17 (81) 58.1–94.6 | 5 (100)47.8–100.0 | 25 (66) 48.7–80.4 | 3 (38) 8.5–75.5 |
Complete response | 1 (5) | 5 (100) | 5 (13) | 1 (13) |
Partial response | 16 (76) | 0 | 20 (53) | 2 (25) |
Stable disease | 1 (5) | 0 | 4 (11) | 0 |
Progressive disease | 1 (5) | 0 | 3 (8) | 0 |
Non-CR/non-PD | 1 (5) | 0 | 4 (11) | 4 (50) |
Missing/unevaluable | 1 (5) | 0 | 2 (5) | 1 (13) |
Median time to event, months 95% CI | ||||
Duration of response* | NE 29.4–NE‡ | 8 5.8–NE‡ | 18.4 8.7–21.5 | 22.5 9.2–NE‡ |
Progression-free survival* | 30.3 30.3–NE‡ | 8.9 6.7–NE‡ | 21.1 10.2–28.9 | 11.9 2.8–23.4 |
Overall survival | NE NE‡ | – | 30.9 22.4–NE‡ | – |
*By BICR; †Baseline CNS metastases by BICR; ‡Data are not mature NE, not estimable
Clinical trial identification
Editorial acknowledgement
This study is sponsored by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance, under the direction of the authors, was provided by Claire White, PhD, of Ashfield MedComms, an Inizio company, and funded by F. Hoffmann-La Roche Ltd.
Legal entity responsible for the study
F. Hoffmann-La Roche Ltd.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche; Financial Interests, Personal, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui BeiGene, Roche, Hansoh. C. Chiu: Financial Interests, Personal, Other, Honoraria: AstraZeneca, Boehringer-Ingelhein, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, Takeda; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Eli Lilly, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Roche. H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer-Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. C. Lin: Financial Interests, Personal, Other, Travel support: BeiGene, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo, Novartis, AbbVie, PharmaEngine, Merck KGaA; Financial Interests, Personal, Invited Speaker: Eli Lilly, Novartis, Roche. Z. Zhang: Financial Interests, Institutional, Full or part-time Employment: F. Hoffmann-La Roche Limited, Beijing, China. N. Zhao, T. Xu: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. M. Hou: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03